Amivantamab Significantly Improves PFS Vs Chemotherapy in EGFR+ NSCLC
October 4th 2023Investigators will present overall survival and objective response data from the phase 3 MARIPOSA-2 trial assessing amivantamab in EGFR exon 19 deletion–positive non–small cell lung cancer at a future scientific meeting.
Pomalidomide Combo Yields PFS/OS Benefits in R/R Multiple Myeloma
October 1st 2023Pomalidomide plus bortezomib and dexamethasone confers a larger progression-free survival benefit than bortezombib plus dexamethasone among patients with relapsed/refractory multiple myeloma in the phase 3 OPTIMISMM trial.
Real-world Teclistamab Use Finds Comparable Efficacy With MajesTec-1 in Multiple Myeloma
September 29th 2023When teclistamab was evaluated in a real-world setting, investigators determined that efficacy was similar between that and the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.
Data Confirm Dara-KRd/Double Transplant Benefit in Newly Diagnosed Myeloma
September 29th 2023Investigators report a low rate of high-grade hematologic adverse effects following treatment with induction Dara-KRd and consolidation double transplant in patients with high-risk, newly diagnosed multiple myeloma.